Advertisement

Clinical and Translational Oncology

, Volume 20, Issue 5, pp 613–618 | Cite as

Oncologist’s knowledge and implementation of guidelines for breakthrough cancer pain in Spain: CONOCE study

  • R. López López
  • C. Camps Herrero
  • P. Khosravi-Shahi
  • V. Guillem Porta
  • A. Carrato Mena
  • J. Garcia-Foncillas
  • J. J. Cruz Hernández
  • P. Gascón Vilaplana
  • A. Antón Torres
  • E. Diaz-Rubio
  • M. Feyjoo Saus
  • E. Aranda Aguilar
Research Article

Abstract

Purpose

Breakthrough cancer pain (BTcP) has been shown to be a prevalent and poor prognostic factor for oncologic patients, which remain under diagnosed and undertreated. In 2012, the Spanish Society of Medical Oncology (SEOM) published a clinical practice guideline (CPG) for the treatment of cancer pain which specifically addressed the management of BTcP.

Methods

Fundación ECO designed a qualitative study using an Internet-based survey to investigate the attitudes toward, compliance with, and use of SEOM Guideline.

Results

A total of 83 oncologists with a mean experience of 13 years responded. Overall, 82% were aware of different guidelines to manage BTcP. Notably, attitudes toward guidelines were highly positive and there was nearly unanimous agreement that CPG provided the best scientific evidence available (99%), on the minimum information to be gathered for the medical history (100%), on the need for a specific treatment for BTcP (100%), and fentanyl as the first-choice drug (99%). Interestingly, there were discrepancies between what oncologists agreed with and what they do in clinical practice. In fact, 87.6% declare full compliance with SEOM guideline, although adherence to registration of BTcP data in medical records ranged from 30.1 to 91.6% (mean 64.5%); therapeutic management compliance was higher ranging from 75.9 to 91.6%. Main barriers identified were time pressure together with vague statements and limited dissemination of the guidelines.

Conclusion

Despite oncologist’s clinical practice is increasingly guided by GPC, it suffers from limited compliance, at least in part due to suboptimal statements. Improved dissemination and education are needed to enhance guideline implementation.

Keywords

Breakthrough pain Oncologists Practice guidelines Pain management Attitude of health personnel Clinical competence 

Notes

Acknowledgements

The authors acknowledge all the medical oncologists who answered the survey for their contribution to the study.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Funding

This study was funded by Kyowa Kirin Farmacéutica S. L.U. through Fundación ECO.

Ethical approval

This study was approved by the Hospital Universitario Reina Sofía de Córdoba Clinical Research Ethics Committee and conforms to the ethical norms and standards in the 1964 Declaration of Helsinki and its later amendments. The manuscript does not contain clinical studies or patient data.

References

  1. 1.
    Foley KM. Pain assessment and cancer pain syndromes. In: Doyle D, Hanks GWC, Calman K, Cherny N, editors. Oxford textbook of palliative medicine. 3rd ed. New York: Oxford University Press; 2003.Google Scholar
  2. 2.
    Breivik H, Cherny N, Collett B, de Conno F, Filbet M, Foubert AJ, et al. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol. 2009;20:1420–33.CrossRefPubMedGoogle Scholar
  3. 3.
    Greco MT, Roberto A, Corli O, Deandrea S, Bandieri E, Cavuto S, et al. Quality of cancer pain management: an update of a systematic review of under treatment of patients with cancer. J Clin Oncol. 2014;32:4149–54.CrossRefPubMedGoogle Scholar
  4. 4.
    Porta-Sales J, Garzón-Rodriguez C, Juliá-Torras J, Casals Merchán M. Cancer-related breakthrough pain. Med Clin (Barc). 2010;135:280–5.CrossRefGoogle Scholar
  5. 5.
    Deandrea S, Corli O, Consonni D, Villani W, Greco MT, Apolone G. Prevalence of breakthrough cancer pain: a systematic review and a pooled analysis of published literature. J Pain Symp Manag. 2014;47:57–75.CrossRefGoogle Scholar
  6. 6.
    Davies A, Zeppetella G, Andersen S, Damkier A, Vejlgaard T, Nauck F, et al. Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies. Eur J Pain. 2011;15:756–63.CrossRefPubMedGoogle Scholar
  7. 7.
    Haugen DF, Hjermstad MJ, Hagen N, Caraceni A, Kaasa S, European Palliative Care Research Collaborative (EPCRC). Assessment and classification of cancer breakthrough pain: a systematic literature review. Pain. 2010;149:476–82.CrossRefPubMedGoogle Scholar
  8. 8.
    Escobar Álvarez Y, Biete Solà A, Camba Rodríguez M, Gálvez Mateos R, Mañas Rueda A, Rodríguez Sánchez CA. et al [Diagnosis and treatment of breakthrough cancer pain: consensus recommendations]. Rev Soc Esp Dolor. 2013;20:61–8.CrossRefGoogle Scholar
  9. 9.
    Virizuela JA, Escobar Y, Cassinello J, Borrega P; SEOM (Spanish Society of Clinical Oncology). Treatment of cancer pain: Spanish Society of Medical Oncology (SEOM) recommendations for clinical practice. Clin Transl Oncol. 2012;14:499–504.Google Scholar
  10. 10.
    Ripamonti CI, Santini D, Maranzano E, Berti M, Roila F; ESMO Guidelines Working Group. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23:vii139–54.Google Scholar
  11. 11.
    Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G; Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. The management of cancer-related breakthrough pain: recommendations of the task group of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain. 2009;12:331–8.Google Scholar
  12. 12.
    Caraceni A, Davies A, Poulain P, Cortés-Funes H, Panchal SJ, Fanelli G. Guidelines for the management of breakthrough pain in patients with cancer. J Natl Compr Cancer Netw. 2013;11(Suppl 1):S29–36.CrossRefGoogle Scholar
  13. 13.
    Kotzeva A, Guillamón I, Gracia J, Díaz del Campo P, Gich I, Calderón E, et al. Use of clinical practice guidelines and factors related to their uptake: a survey of health professionals in Spain. J Eval Clin Pract. 2014;20:216–24.CrossRefPubMedGoogle Scholar
  14. 14.
    te Boveldt N, Vernooij-Dassen M, Besse K, Vissers K, Engels Y. Adaptation of an evidence-based clinical practice guideline in cancer pain management by medical oncologists: a case vignette study. Support Care Cancer. 2015;23:1409–20.CrossRefGoogle Scholar
  15. 15.
    Luckett T, Davidson PM, Boyle F, Liauw W, Agar M, Green A, et al. Australian survey of current practice and guideline use in adult cancer pain assessment and management: perspectives of oncologists. Asia Pac J Clin Oncol. 2014;10:e99–107.CrossRefPubMedGoogle Scholar
  16. 16.
    Jagsi R, Huang G, Griffith K, Zikmund-Fisher BJ, Janz NK, Griggs JJ, et al. Attitudes toward and use of cancer management guidelines in a national sample of medical oncologists and surgeons. J Natl Compr Cancer Netw. 2014;12:204–12.CrossRefGoogle Scholar
  17. 17.
    Tsiga E, Panagopoulou E, Sevdalis N, Montgomery A, Benos A. The influence of time pressure on adherence to guidelines in primary care: an experimental study. BMJ Open. 2013;3:e002700.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, et al. Why don’t physicians follow clinical practice guidelines? JAMA. 1999;282:1458–65.CrossRefPubMedGoogle Scholar
  19. 19.
    Barth JH, Misra S, Aakre KM, Langlois MR, Watine J, Twomey P, et al. Why are clinical practice guidelines not followed? Clin Chem Lab Med. 2016;54:1133–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Es Berner. Graver ML. Overconfidence as a cause of diagnostic error in medicine. Am J Med. 2008;121:s2–3.Google Scholar
  21. 21.
    Lugtenberg M, Burgers JS, Besters CF, Han D, Westert GP. Perceived barriers to guideline adherence: a survey among general practitioners. BMC Fam Pract. 2011;12:98.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Breuer B, Fleishman SB, Cruciani RA, Portenoy RK. Medical oncologists’ attitudes and practice in cancer pain management: a national survey. J Clin Oncol. 2011;29:4769–75.CrossRefPubMedGoogle Scholar
  23. 23.
    Kwon JH. Overcoming barriers in cancer pain management. J Clin Oncol. 2014;16:1727–33.CrossRefGoogle Scholar
  24. 24.
    Bhatia R, Gibbins J, Forbes K, Reid C. “We all talk about it as though we’re thinking about the same thing.” Healthcare professionals’ goals in the management of pain due to advanced cancer: a qualitative study. Support Care Cancer. 2014;22:2067–73.CrossRefPubMedGoogle Scholar
  25. 25.
    Te Boveldt ND, Vernooij-Dassen MJ, Jansen A, Vissers KC, Engels Y. Pain is not systematically registered in Dutch medical oncology outpatients. Pain Pract. 2015;15:364–70.CrossRefGoogle Scholar
  26. 26.
    Jandhyala R, Fullarton JR, Bennett MI. Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a metaanalysis of comparative trials. J Pain Symp Manag. 2013; 46:573–80.Google Scholar
  27. 27.
    Velázquez Rivera I, Muñoz Garrido JC, García Velasco P, de Enciso IEX, Clavarana LV. Efficacy of sublingual fentanyl vs. Oral morphine for cancer-related breakthrough pain. Adv Ther. 2014;31:107–17.CrossRefPubMedGoogle Scholar
  28. 28.
    Zeppetella G. Evidence-based treatment of cancer-related breakthrough pain with opioids. J Natl Comp Canc Netw. 2013;11:S37–43.CrossRefGoogle Scholar
  29. 29.
    National Collaborating Centre for Cancer (UK). Palliative care for adults: strong opioids for pain relief [Internet]. Cardiff: Royal College of Physicians (UK); 2012. Available from: https://www.nice.org.uk/guidance/cg140. Cited 15 July 2016.
  30. 30.
    Grol R, Dalhuijsen J, Thomas S, Veld C, Rutten G, Mokkink H. Attributes of clinical guidelines that influence use of guidelines in general practice: observational study. BMJ. 1998;317:858–61.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2017

Authors and Affiliations

  • R. López López
    • 1
  • C. Camps Herrero
    • 2
  • P. Khosravi-Shahi
    • 3
  • V. Guillem Porta
    • 4
  • A. Carrato Mena
    • 5
  • J. Garcia-Foncillas
    • 6
  • J. J. Cruz Hernández
    • 7
  • P. Gascón Vilaplana
    • 8
  • A. Antón Torres
    • 9
  • E. Diaz-Rubio
    • 10
  • M. Feyjoo Saus
    • 11
  • E. Aranda Aguilar
    • 12
  1. 1.Comisión Permanente Fundación ECO, Servicio de Oncología MédicaComplejo Universitario de Santiago de CompostelaSantiago De CompostelaSpain
  2. 2.Comisión Permanente Fundación ECOHospital General Universitario de ValenciaValenciaSpain
  3. 3.Servicio de Oncología MédicaHospital Universitario de TorrejónMadridSpain
  4. 4.Comisión Permanente Fundación ECO, Servicio de Oncología MédicaFundación Instituto Valenciano de OncologíaValenciaSpain
  5. 5.Comisión Permanente Fundación ECO, Servicio de Oncología MédicaHospital Universitario Ramón y CajalMadridSpain
  6. 6.Patrono Fundación ECO, Servicio de Oncología MédicaHospital Universitario “Fundación Jiménez Díaz”MadridSpain
  7. 7.Comisión Científica Fundación ECO, Servicio de Oncología MédicaHospital Universitario de SalamancaSalamancaSpain
  8. 8.Comisión Científica Fundación ECO, Servicio de OncologíaFundació ClínicBarcelonaSpain
  9. 9.Comisión Científica Fundación ECO, Servicio de Oncología MédicaHospital Universitario Miguel ServetZaragozaSpain
  10. 10.Presidente Fundación ECO, Servicio de Oncología Médica, Hospital Clínico Universitario San CarlosMadridSpain
  11. 11.Servicio de Oncología MédicaMadridSpain
  12. 12.Comisión Permanente Fundación ECO, Maimonides Institute of Biomedical ResearchHospital Universitario Reina SofíaCórdobaSpain

Personalised recommendations